Adoptive cell therapies offer a promising approach for the treatment of numerous diseases including cancer, autoimmune and infectious diseases. In particular, autologous CAR T cell therapy provides an unparalleled adaptive response to hematological tumors – minimizing the risk of systemic side effects and bio-incompatibility.
Researchers and manufacturers must ensure reproducibility, efficacy and potency before treatments reach the clinic. Hence, efficient tools to monitor potency ex-vivo are essential to ensure safe and consistent cell therapy products.Download this eBook to learn about:
- The current state of CAR T therapies
- Tools to evaluate the potency of novel cell therapies in vitro
- Strategic collaborations to transform manufacturing of cell therapies